Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by [1H]/[19F] magnetic resonance spectroscopy. Cancer Commun 1991 May;3(5):133-9
Date
05/01/1991Pubmed ID
2043424DOI
10.3727/095535491820873353Scopus ID
2-s2.0-0025938542 (requires institutional sign-in at Scopus site) 17 CitationsAbstract
Hexafluoromisonidazole (CCI-103F) is a hypoxic cell label that can be measured by in vivo [1H]/[19F] magnetic resonance spectroscopy (MRS). The retention of CCI-103F in SCCVII tumors was found to be correlated with tumor size, with larger tumors retaining more label. Such a correlation was anticipated, as larger SCCVII tumors have larger hypoxic fractions. A significant but less strong correlation was also found between CCI-103F retention and the fraction of tumor cells surviving after 10 Gy irradiation, with tumors that retained larger amounts of CCI-103F having higher surviving fractions. These results indicated that non-invasive MRS measurement of CCI-103F retention could predict radiosensitivity in SCCVII tumors. The lack of a strong correlation between CCI-103F retention and radiosensitivity, however, indicated that hypoxic fraction was not the only factor influencing radiosensitivity in these tumors.
Author List
Li SJ, Jin GY, Moulder JEMESH terms used to index this publication - Major topics in bold
AnimalsCell Hypoxia
Cell Survival
Gamma Rays
Magnetic Resonance Spectroscopy
Mice
Mice, Inbred C3H
Neoplasms, Experimental
Nitroimidazoles
Radiation Tolerance
Radiography
Radionuclide Imaging
Tumor Cells, Cultured
